Showed high clinical success with 86% freedom from symptomatic recurrence1 Temperature control allows for the safe use of higher RF power in short bursts, enhancing efficacy and efficiency without compromising safety1 IRVINE, Calif., May 15, 2023 /PRNewswire/ — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced … Read more
PLANO, Texas, May 15, 2023 /PRNewswire/ — U.S. Renal Care (USRC or “the Company”), the nation’s largest privately held and fastest growing kidney care provider, today announced that it has successfully raised $328 million in new capital to further accelerate the Company’s growth and expansion plans. The new capital will be invested in programs focused on innovation … Read more
SAN DIEGO, May 14, 2023 /PRNewswire/ — Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) … Read more
SAN DIEGO, May 12, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Institutional Shareholder Services (“ISS”), a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein. Illumina’s Annual Meeting is scheduled … Read more
SAN DIEGO, May 12, 2023 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the abstract ‘Safety and efficacy findings from a phase 1b/2 open-label study of a novel combination of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced … Read more
$29.1 million in cash and cash equivalents as of March 31, 2023; $15 million registered direct offering in May 2023 extends runway through May 2024 Halo-Lido Phase 2b trial completed with topline results anticipated by end of calendar Q2 2023 CRANFORD, N.J., May 12, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: … Read more
HOUSTON, May 12, 2023 /PRNewswire/ — Today, FemTec Health, Inc. announced the purchase of its Birchbox assets, effective April 12, 2023, by Retention Brands. Early this year as part of its strategic tightening around core healthcare businesses, FemTec Health engaged a national financial consulting firm to advise and explore possibilities for the sale of some of … Read more
Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1 2023 providing projected cash runway into Q4 2024 LEXINGTON, Mass., May 12, 2023 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company … Read more
50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy DENVER, May 12, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that the company’s MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting … Read more
SAN DIEGO, 12 mai 2023 /PRNewswire/ — « Aujourd’hui, nous sommes heureux d’annoncer que le test de mutation FLT3 LeukoStrat® CDx d’Invivoscribe a été approuvé par BSI (Pays-Bas) et l’EMA en tant que test CDx de classe C, répondant aux nouvelles exigences rigoureuses de l’IVDR (règlement (UE) 2017/746). Invivoscribe est l’une des premières sociétés au monde à obtenir une approbation IVDR … Read more